Pillar Biosciences Partners with AstraZeneca to Accelerate Access to Liquid Biopsy Testing (September, 2024)
In September 2024, Pillar Biosciences announced a strategic partnership with AstraZeneca to expand laboratory access to molecular testing in Europe and the UK using rapid, affordable NGS-based liquid biopsy tumor profiling kits. The collaboration leverages Pillar’s oncoReveal™ liquid biopsy panels to deliver highly sensitive and specific tumor genetic variant detection, enabling local labs and clinicians to obtain actionable genomic results in just a few days. This partnership aims to accelerate access to precision therapies for cancer patients by making advanced testing more widely available and reducing turnaround times.
新闻链接 | News Link: https://www.prnewswire.com/news-releases/pillar-biosciences-partners-with-astrazeneca-to-help-accelerate-access-to-liquid-biopsy-testing-302241990.html
Related Posts
Unveiled the “Shushan” cryogenic CMOS quantum control chipset (March, 2025)
Unveiled the “Shushan” cryogenic CMOS quantum control chipset, including “Gongga” (superconducting qubit control), “Emei” (qubit readout), and “Xiling” (silicon-based qubit control) chips. “Xiling” was presented at ISSCC 2025, reducing system noise and power consumption for large-scale qubit arrays. Ne
Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences. According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer
Yilei Laser Reports Strong Order Backlog and Expands into AI and Humanoid Robotics (June 18, 2025)
At its 2025 performance briefing, Yilei Laser reported a strong order backlog, with a significant portion from large cylindrical full-tab battery assembly lines and overseas market breakthroughs. The company made substantial progress in solid-state battery equipment, perovskite solar, and semiconductor AMHS systems. Yilei is actively expanding into humanoid rob
NGS test completed in one day, lung and colon cancer test kits receive FDA approval
NGS (next generation sequencing technology), also known as high-throughput sequencing technology. It is commonly used for genetic disease screening, prenatal testing or diagnosis, oncology clinical diagnosis, pharmacogenomic testing, cancer chemotherapy and treatment, and single gene disease screening or diagnosis. It is capable of sequencing hundreds of thousa
Leave a Reply